Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens

JAMA

Volumn 283, Issue 2, 2000, Pages 229-234

  Havlir, Diane V ^a   Hellmann, Nick S ^b   Petropoulos, Christos J ^b   Whitcomb, Jeannette M ^b   Collier, Ann C ^d   Hirsch, Martin S ^c   Tebas, Pablo ^e   Sommadossi, Jean Pierre ^f   Richman, Douglas D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MONOGRAM BIOSCIENCES   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e WASHINGTON UNIVERSITY   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFECT; DRUG POTENCY; DRUG SENSITIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TARGET CELL; VIRUS LOAD; VIRUS MUTANT; VIRUS REPLICATION;

EID: 0034639490     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.283.2.229     Document Type: Article

References (37)

1. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998. JAMA. 1998;280:78-86.
2. Fätkenheuer G, Thiesen A, Rockstroh J, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS. 1997;11:F113-F116.
3. Mocroft A, Gill MJ, Davidson W, Phillips AN. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS. 1998;12:2161-2167.
4. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734-739.
5. Wein LM, D'Amato RM, Perelson AS. Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads. J Theor Biol. 1998;192:81-98.
6. Havlir DV, Marschner IC, Hirsch MS, et al. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med. 1998;339:1261-1268.
7. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 1995;374:569-571.
8. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med. 1996;2:760-766.
9. 2-symmetric protease inhibitor. J Virol. 1994;68:2016-2020.
10. Gulnik SV, Suvorov LI, Liu B, et al. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry. 1995;34:9282-9287.
11. Nijhuis M, Schuurman R, de Jong D, et al. Selection of HIV-1 variants with increased fitness during ritonavir therapy. In: International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication; June 25-28, 1997; St Petersburg, Fla. Abstract 92.
12. Mammano F, Petit C, Clavel F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1. J Virol. 1998;72:7632-7637.
13. Little SJ, Daar ES, D'Aquila RT, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA. 1999;282:1142-1149.
14. Hellmann N, Johnson P, Petropoulos C. Validation of the performance characteristics of a novel, rapid phenotypic drug susceptibility assay: PhenoSense HIV. In: Programs and abstracts of the 3rd International Workshop on Drug Resistance and Treatment Strategies; June 23-26, 1999; San Diego, Calif. Abstract 51.
15. Gunthard HF, Wong JK, Ignacio CC, Havlir DV, Richman DD. Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. AIDS Res Hum Retroviruses. 1998;14:869-876.
16. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection. JAMA. 1998;279:1984-1991.
17. Shafer RW, Winters MA, Palmer S, Merigan TC. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med. 1998;128:906-911.
18. Condra JH, Holder DJ, Schleif WA, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol. 1996;70:8270-8276.
19. Young B, Johnson S, Bahktiari M, et al. Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure. J Infect Dis. 1998;178:1497-1501.
20. Mayers DL, Gallahan DL, Martin GJ, et al. Drug resistance genotypes from plasma virus of HIV-infected patients failing combination drug therapy. In: International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication; June 25-28, 1997; St Petersburg, Fla. Abstract 80.
21. Holder DJ, Condra JH, Schleif WA, Chodakewitz J, Emini EA. Virologic failure during combination therapy with Crixivan and RT inhibitors is often associated with expression of resistance-associated mutations in RT only. In: 6th Conference on Retroviruses and Opportunistic Infections; January 31 to February 4, 1999; Chicago, Ill. Abstract 492.
22. Descamps D, Peytavin G, Calvez V, et al. Virologic failure, resistance and plasma drug measurements in induction maintenance therapy trial (Anrs 072, Trilege). In: 6th Conference on Retroviruses and Opportunistic Infections; January 31 to February 4, 1999; Chicago, Ill. Abstract 493.
23. Richman D, Shih CK, Lowy I, et al. Human immunodeficiency virus type 1 mutants resistant to non-nucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci U S A. 1991;88: 11241-11245.
24. Schinazi RF, Lloyd RM Jr, Nguyen MH, et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother. 1993;37:875-881.
25. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A. 1993;90:5653-5656.
26. Boucher CA, Cammack N, Schipper P, et al. High-level resistance to enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 1993;37:2231-2234.
27. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 1995;171:1411-1419.
28. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995;373:117-122.
29. Havlir DV, Eastman S, Gamst A, Richman DD. Nevirapine-resistant human immunodeficiency virus. 1 Virol. 1996;70:7894-7899.
30. Bacheler L, Weislow O, Snyder S, Hanna G, D'Aquila R. The Sustiva Resistance Study Team: virological resistance to efavirenz. In: 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 41213.
31. Larder B. Nucleosides and foscarnet mechanisms. In: Richman DD, ed. Antiviral Drug Resistance. Chichester, England: John Wiley & Sons; 1996:169-190.
32. de Jong MD, Veenstra J, Stilianakis NI, et al. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine. Proc Natl Acad Sci U S A. 1996;93:5501-5506.
33. Markowitz M, Ho DD. Protease inhibitors -mechanisms and clinical aspects. In: Richman DD, ed. Antiviral Drug Resistance. Chichester, England: John Wiley & Sons; 1996:261-278.
34. Zennou V, Mammano F, Paulous S, Mathez D, Clavel F. Loss of viral fitness associated with multiple gag and gag-pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J Virol. 1998;72:3300-3306.
35. McLean AR, Nowak MA. Competition between zidovudine-sensitive and zidovudine-resistant strains of HIV. AIDS 1992;6:71-79.
36. Lee CG, Gottesman MM, Cardarelli CO, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry. 1998;37:3594-3601.
37. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest. 1998;101:289-294.